These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 572413)

  • 1. The effect of monoamine oxidase inhibitors on some arylalkylamines in rate striatum.
    Philips SR; Boulton AA
    J Neurochem; 1979 Jul; 33(1):159-67. PubMed ID: 572413
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversible, amine--selective effects of acute and chronic brofaromine treatment in the rat.
    Dyck LE; Boulton AA
    Life Sci; 1992; 51(1):59-66. PubMed ID: 1614274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J-508: their properties and applications.
    Fowler CJ; Oreland L; Callingham BA
    J Pharm Pharmacol; 1981 Jun; 33(6):341-7. PubMed ID: 6115003
    [No Abstract]   [Full Text] [Related]  

  • 4. Influence of substrate in the inhibition of rat liver and brain monoamine oxidase.
    Fuller RW
    Arch Int Pharmacodyn Ther; 1968 Jul; 174(1):32-7. PubMed ID: 4386711
    [No Abstract]   [Full Text] [Related]  

  • 5. Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain.
    Garrick NA; Murphy DL
    Psychopharmacology (Berl); 1980; 72(1):27-33. PubMed ID: 6781004
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple forms of monoamine oxidase. Comparison of in vitro and in vivo inhibition patterns.
    Collins GG; Youdim MB; Sandler M
    Biochem Pharmacol; 1972 Jul; 21(14):1995-8. PubMed ID: 4405452
    [No Abstract]   [Full Text] [Related]  

  • 7. Cumulative effects of irreversible MAO inhibitors in vivo.
    Felner AE; Waldmeier PC
    Biochem Pharmacol; 1979 Apr; 28(7):995-1002. PubMed ID: 444293
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of different substrates on the inhibition of rat brain and liver monoamine oxidase by arylalkylhydrazines.
    Popov N; Matthies H; Lietz W; Thiemann C; Jassmann E
    Biochem Pharmacol; 1970 Aug; 19(8):2413-8. PubMed ID: 5520601
    [No Abstract]   [Full Text] [Related]  

  • 9. Reciprocal changes in striatal dopamine and beta-phenylethylamine induced by reserpine in the presence of monoamine oxidase inhibitors.
    Juorio AV; Greenshaw AJ; Wishart TB
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Dec; 338(6):644-8. PubMed ID: 3149722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Release of some endogenous trace amines from rat striatal slices in the presence and absence of a monoamine oxidase inhibitor.
    Dyck LE
    Life Sci; 1989; 44(17):1149-56. PubMed ID: 2716465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoamine oxidase inhibitors and histamine metabolism.
    Benedetti MS; Ancher JF; Sontag N
    Experientia; 1980 Jul; 36(7):818-10. PubMed ID: 6772465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early effects of monoamine oxidase inhibitors on dopamine metabolism and monoamine oxidase activity in the neostriatum of the rat.
    Javoy F; Youdim MB; Agid Y; Glowinski J
    J Neural Transm; 1973; 34(4):279-89. PubMed ID: 4149516
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of monoamine oxidase inhibitors on qualitative alterations in enzymatic properties of mitochondrial monoamine oxidases.
    Abdel Samed MH; Akopyan ZI; Veryovkina IV; Kulygina AA; Gorkin VZ
    Biochem Pharmacol; 1971 Oct; 20(10):2571-7. PubMed ID: 5114498
    [No Abstract]   [Full Text] [Related]  

  • 14. Alteration of dopamine synthesis in rat striatum subsequent to selective type A monoamine oxidase inhibition.
    Schoepp DD; Azzaro AJ
    J Neurochem; 1981 Aug; 37(2):527-30. PubMed ID: 6790675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs.
    Neff NH; Yang HY
    Life Sci; 1974 Jun; 14(11):2061-74. PubMed ID: 4603266
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo.
    Robinson DS; Lovenberg W; Keiser H; Sjoerdsma A
    Biochem Pharmacol; 1968 Jan; 17(1):109-19. PubMed ID: 4384242
    [No Abstract]   [Full Text] [Related]  

  • 17. In vivo studies on the effect of monoamine oxidase inhibitors on dopamine and serotonin metabolism in rat brain areas.
    Clement HW; Grote C; Wesemann W
    J Neural Transm Suppl; 1990; 32():85-8. PubMed ID: 2128514
    [No Abstract]   [Full Text] [Related]  

  • 18. Thyroid iodide transport is reduced by administration of monoamine oxidase A inhibitors to rats.
    Cabanillas AM; Masini-Repiso AM; Costamagna ME; Pellizas C; Coleoni AH
    J Endocrinol; 1994 Nov; 143(2):303-8. PubMed ID: 7829993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular turnover numbers of different forms of mitochondrial monoamine oxidase in rat.
    Egashira T; Ekstedt B; Kinemuchi H; Wiberg A; Oreland L
    Med Biol; 1976 Aug; 54(4):272-7. PubMed ID: 957813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoamine oxidase inhibiting properties of SU-11,739 in the rat. Comparison with pargyline, tranylcypromine and iproniazid.
    Maître L
    J Pharmacol Exp Ther; 1967 Jul; 157(1):81-8. PubMed ID: 6029494
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.